Skip to main content

Advertisement

SpringerLink
Log in

Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimens were used before and after treatment with nivo. This HNSCC case is the first report of a good response when the same cytotoxic chemotherapy regimen was used before and after nivo. In addition, the efficacy of anti-epidermal growth factor receptor antibody after nivo treatment may be better than without exposure to nivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Daste A, de Mones E, Digue L et al (2017) Immunotherapy in head and neck cancer: need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. Oral Oncol 64:e1–e3

    Article  CAS  PubMed  Google Scholar 

  3. Schvartsman G, Peng SA, Bis G et al (2017) Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90–95

    Article  PubMed  Google Scholar 

  4. Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE- 024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 8:JCO1800149. https://doi.org/10.1200/JCO.18.00149

    Article  Google Scholar 

  5. Leger PD, Rothschild S, Castellanos E et al (2017) Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer. J Clin Oncol 35 suppl:abstr 9084

    Article  Google Scholar 

  6. Peng J, Hamanishi J, Matsumura N et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75:5034–5045

    Article  CAS  PubMed  Google Scholar 

  7. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73

    Article  CAS  PubMed  Google Scholar 

  8. Carson WE III, Shapiro CL, Crespin TR, Thornton LM, Andersen BL (2004) Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10:3401–3409

    Article  CAS  PubMed  Google Scholar 

  9. Mallick P, Basu S, Moorthy B, Ghose R (2017) Role of toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Toxicol In Vitro 41:75–82

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Roy A, Singh MS, Upadhyay P, Bhaskar S (2013) Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int J Pharm 445:171–180

    Article  CAS  PubMed  Google Scholar 

  11. Agero AL, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657

    Article  PubMed  Google Scholar 

  12. Stintzing S, Kapaun C, Laubender RP et al (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132:236

    Article  CAS  PubMed  Google Scholar 

  13. Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8:173

    Article  CAS  PubMed  Google Scholar 

  14. Hitt R, Irigoyen A, Cortes-Funes H et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23:1016–1022

    Article  CAS  PubMed  Google Scholar 

  15. Jie HB, Srivastava RM, Argiris A et al (2017) Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res 5:408–416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bonomo P, Desideri I, Loi M et al (2018) Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: a phase I/II study (DUCRO). Clin Transl Radiat Oncol 9:42–47

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None of the authors have financial disclosures or funding support.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Takashi Koyama, Motoo Nomura, Doi Keitaro & Manabu Muto

  2. Department of Rheumatology and Clinical Immunology, Kyoto University Hospital, Kyoto, Japan

    Takashi Koyama

  3. Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Ichiro Tateya

Authors
  1. Takashi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Motoo Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Doi Keitaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ichiro Tateya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manabu Muto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Motoo Nomura.

Ethics declarations

Ethical approval

All procedures performed in study involving human participant was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

None of the authors have conflicts of interest to declare.

Informed consent

Informed consent was obtained from a participant included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koyama, T., Nomura, M., Keitaro, D. et al. Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy. Int Canc Conf J 8, 86–88 (2019). https://doi.org/10.1007/s13691-019-00360-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-019-00360-y

Keywords

Search

Navigation